Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gammaagonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis

Journal of Physiology and Pharmacology

Volumn 64, Issue 5, 2013, Pages 587-595

  Celinski, K ^a   Dworzanski, T ^a   Fornal, R ^b   Korolczuk, A ^a   Madro, A ^a   Brzozowski, T ^c   Slomka, M ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b John Paul II Public Provincial Hospital   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Colitis; Dextran sodium sulfate; Peroxisome proliferator activated receptors ; Prevention; Proinflammatory cytokines; Rosiglitazone; Troglitazone

Indexed keywords

INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; HISTOPATHOLOGY; INTERFERON BLOOD LEVEL; INTERFERON TISSUE LEVEL; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 10 TISSUE LEVEL; INTERLEUKIN 2 BLOOD LEVEL; INTERLEUKIN 2 TISSUE LEVEL; INTERLEUKIN 4 BLOOD LEVEL; INTERLEUKIN 4 TISSUE LEVEL; LARGE INTESTINE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TH1 CELL; TH2 CELL; TISSUE HOMOGENATE; TISSUE LEVEL; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHROMANS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; INTESTINAL MUCOSA; MALE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84888213779     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Celinski K, Dworzanski T, Korolczuk A, et al. Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate - induced colitis in rats. J Physiol Pharmacol 2011; 62: 347-356.
2. Celinski K, Madro A, Prozorow-Krol B, et al. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-g)-specific agonist, as a modulator in experimental acute pancreatitis. Med Sci Monit 2009; 15: 21-29.
3. Celinski K, Dworzanski T, Prozorow-Krol B, Korolczuk A. The role of PPAR-g receptors in gastrointestinal inflammation diseases. Gastroenterol Pol 2009; 16: 51-56.
4. Andersen V, Christensen J, Ernst A, et al. Polymorphisms in NF-kB, PXR, LXR, PPARg and risk of inflammatory bowel disease. World J Gastroenterol 2011; 17: 197-206.
5. Hontecillas R, Horne WT, Climent M, et al. Immunoregulatory mechanisms of macrophage PPAR-g in mice with experimental inflammatory bowel disease. Mucosal Immunol 2011; 4: 304-313.
6. Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. J Pharm Pharmacol 2012; 64: 161-171.
7. Xiang GQ, Tang SS, Jiang LY, et al. PPARg agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol 2012; 64: 589-596.
8. Ma JJ, Zhang T, Fang N, Zou Y, Gong QH, Yu LM, Chen DX. Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARg). J Pharm Pharmacol 2012; 64: 719-726.
9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
10. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferators activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
11. Willson TM, Cobb JE, Cowan DJ, et al. The structure activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
12. Celinski K, Dworzanski T, Korolczuk A, et al. Comparison of main models of experimental colitis essential for studies on novel therapies of inflammatory bowel disease. Gastroenterol Pol 2010; 17: 195-202.
13. Celinski K, Dworzanski T, Fornal R, Korolczuk A, Madro A, Slomka M. Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis. J Physiol Pharmacol 2012; 63: 631-640.
14. Shizuma T, Ishiwata K, Nagano M, Mori H, Fukuyama N. Protective effects of Kurozu and Kurozu Moromimatsu on dextran sulfate sodium-induced experimental colitis. Dig Dis Sci 2011; 56: 1387-1392.
15. Nakashima T, Maeda T, Nagamoto H, Kumakura T, Takai M, Mori T. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Dig Dis Sci 2005; 50 (Suppl. 1): 124-S131.
16. Li H, Wu WK, Li ZJ, et al. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br J Pharmacol 2010; 160: 1352-1361.
17. Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S. Embelin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol 2011; 11: 724-731.
18. Cancado GG, Fiuza JA, de Paiva NC, et al. Hookworm products ameliorate dextran sodium sulfate-induced colitis in BALB/c mice. Inflamm Bowel Dis 2011; 17: 2275-2286.
19. Vasina V, Broccoli M, Ursino MG, et al. Non-peptidyl low molecular weight radical scavenger IAC attenuates DSS-induced colitis in rats. World J Gastroenterol 2010; 16: 3642-3650.
20. Van Dop WA, Marengo S, te Velde AA, et al. The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice. Immunol Lett 2010; 131: 33-39.
21. Yamamoto K, Ninomiya Y, Iseki M, et al. 4-Hydroxy-docosahexaenoic acid, a potent peroxisome proliferator-activated receptor gamma agonist alleviates the symptoms of DSS-induced colitis. Biochem Biophys Res Commun 2008; 367: 566-572.
22. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000; 62: 240-248.
23. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
24. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink R P, Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol 2007; 27: 275-283.
25. Takaki K, Mitsuyama K, Tsuruta O, Toyonaga A, Sata M. Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res 2006; 55: 10-15.
26. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon Dela Lastra C. Rosiglitazone, a PPARg ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur J Pharmacol 2007; 562: 247-258.
27. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8: 330-339.
28. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001; 96: 3323-3328.
29. Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 2008; 14: 114-119.
30. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo controlled trial. Gastroenterology 2008; 134: 688-695.
31. Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 2006; 10: 349-360.
32. Tolman K G. The safety of thiazolidinediones. Expert Opin Drug Saf 2011; 10: 419-428.